Richard Gonzalez - AbbVie Chairman of the Board, CEO
| 4AB Stock | EUR 156.94 3.66 2.39% |
Chairman
Mr. Richard A. Gonzalez is the Chairman of the Board, Chief Executive Officer of the Company. Mr. Gonzalez is the chairman and chief executive officer of AbbVie. He served as Abbott executive vice president of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as president, Abbott Ventures Inc., Abbott medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including Abbott president and chief operating officer president, chief operating officer of Abbott Medical Products Group senior vice president and president of Abbott former Hospital Products Division vice president and president of Abbott Health Systems Division and divisional vice president and general manager for Abbott Diagnostics Operations in the United States and Canada. As a result of his service as Abbott executive vice president, Pharmaceutical Products Group, his previous service as Abbott president and chief operating officer and his more than 30year career at Abbott, Mr. Gonzalez has developed valuable business, management and leadership experience, as well as extensive knowledge of AbbVie and its global operations. Mr. Gonzalez experience and knowledge enable him to contribute to AbbVie board key insights into strategic, management, and operational matters. since 2013.
| Age | 69 |
| Tenure | 11 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Bruce Karsh | NorAm Drilling AS | 60 | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Vice President Controller | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President CFO | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Senior Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, CEO | ||
| Brian Durkin, Vice President Controller | ||
| Thomas Hurwich, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Senior Vice President - Human Resources | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
| Roy Roberts, Independent Director | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 331.38 B | |||
| Shares Outstanding | 1.77 B | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 71.51 % | |||
| Price To Earning | 22.27 X | |||
| Price To Book | 18.07 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AbbVie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AbbVie's short interest history, or implied volatility extrapolated from AbbVie options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |